Myasthenia gravis and autoimmune overlap: Prognostic insight

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Autoimmune diseases (ADs) often co-occur with myasthenia gravis (MG), indicating shared genetic and immunological pathways.
• The prognostic impact of these co-occurring ADs on MG progression is not well-understood.
• This study investigates AD prevalence, clinical features, and prognosis in Turkish MG patients.

Purpose of the Study:

• To determine the prevalence and clinical characteristics of comorbid ADs in a cohort of myasthenia gravis patients.
• To evaluate the impact of co-occurring ADs on MG severity, treatment response, and long-term prognosis.
• To identify specific patterns or outcomes associated with ADs in MG patients.

Main Methods:

• Retrospective analysis of 302 myasthenia gravis patients treated between 2010 and 2024.
• Classification of patients into groups with and without comorbid ADs.
• Comparison of clinical features, disease severity, treatment strategies, and prognostic outcomes between groups.

Main Results:

• 13.6% of MG patients had at least one comorbid AD, most commonly autoimmune thyroid disease (10.6%).
• No significant differences in MG severity, thymectomy rates, exacerbations, or overall outcomes were observed between patients with and without ADs.
• Female patients with ADs showed increased myasthenic exacerbations and higher rituximab utilization.

Conclusions:

• Comorbid ADs do not appear to significantly affect the overall severity or prognosis of myasthenia gravis.
• Female MG patients with ADs exhibit a higher frequency of myasthenic exacerbations and increased use of rituximab.
• Early identification and management of ADs in MG patients are crucial for optimizing care and warrant further research.